b
r
c
bacteri
infect
antibiot
resist
bacteria
becom
grow
problem
past
decad
result
center
diseas
control
predict
death
result
microorgan
cancer
combin
current
mani
tradit
model
use
studi
bacteri
infect
fail
precis
replic
vivo
bacteri
environ
model
often
fail
incorpor
fluid
flow
biomechan
cue
intercellular
interact
hostbacteria
interact
even
simpl
inclus
relev
physiolog
protein
cultur
media
result
inadequ
model
often
poor
correl
vitro
vivo
assay
limit
therapeut
potenti
thu
urgenc
establish
vitro
ex
vivo
system
investig
mechan
underli
bacteri
infect
discov
newag
therapeut
bacteri
infect
dire
review
present
updat
current
vitro
ex
vivo
model
comprehens
chang
landscap
tradit
microbiolog
assay
provid
compar
analysi
previou
research
variou
establish
organdiseas
model
lastli
provid
insight
futur
techniqu
may
accur
test
new
formul
meet
grow
demand
antibiot
resist
bacteri
infect
commonli
varieti
inconsist
vitro
vivo
model
progress
util
antibioticdrug
develop
pathophysiolog
studi
system
rang
simpl
vitro
model
use
microtit
plate
assay
flow
cell
complex
http
doi
rise
number
bacteri
infect
especi
antibiot
resist
bacteria
becom
global
threat
public
health
recent
decad
accord
center
diseas
control
prevent
cdc
report
antibiot
resist
threat
us
million
peopl
becom
infect
antibiot
resist
bacteria
unit
state
alon
everi
year
directli
result
death
toll
peopl
year
mani
die
infect
complic
furthermor
infect
caus
drug
resist
bacteria
often
requir
extend
hospit
stay
expens
treatment
add
consider
econom
burden
healthcar
system
estim
high
billion
addit
emerg
antibiot
resist
concern
also
rais
infect
associ
varieti
medic
devic
includ
joint
prosthes
heart
valv
pacemak
cathet
deviceassoci
infect
typic
caus
microorgan
grow
biofilm
introduc
via
surgeri
implant
treatment
infect
gener
challeng
requir
prolong
antibiot
therapi
even
revis
surgeri
inevit
associ
increas
patient
suffer
high
cost
final
biofilm
also
domin
numer
chronic
bacteri
infect
pneumonia
cystic
fibrosi
patient
chronic
wound
treatment
chronic
condit
remain
signific
challeng
healthcar
system
worldwid
collect
total
annual
cost
associ
biofilm
infect
estim
excess
billion
unit
state
alon
result
half
million
death
effici
diagnos
treat
prevent
devast
bacteri
infect
better
understand
mechan
involv
format
virul
persist
use
physiolog
relev
model
critic
need
wide
accept
model
today
vitro
vivo
provid
accur
environ
test
new
antibacteri
approach
contribut
poor
understand
limit
bacteria
adhes
growth
biofilm
format
vivo
model
involv
rodent
rabbit
pig
vitro
model
wide
use
antimicrobi
suscept
screen
cheap
easi
set
amen
highthroughput
design
autom
vivo
model
remain
best
option
avail
safeti
efficaci
evalu
indispens
connect
vitro
experi
clinic
trial
antimicrobi
interest
must
demonstr
suffici
activ
vivo
follow
vitro
evalu
justifi
initi
clinic
trial
addit
vivo
system
also
invalu
toward
investig
diseas
pathogenesi
complex
interact
host
pathogen
exampl
causal
agent
sever
infecti
diseas
includ
bacillu
anthraci
mycobacterium
tuberculosi
rabi
viru
uncov
use
anim
model
pharmaceut
devic
develop
perspect
vitro
vivo
model
instrument
screen
effect
strategi
fight
bacteri
infect
albeit
sometim
contradictori
result
one
notabl
exampl
discoveri
first
sulfonamid
drug
prontosil
target
broad
spectrum
gramposit
cocci
drug
effect
pneumococc
infect
mice
model
even
though
activ
identifi
use
vitro
model
caus
us
paus
inappropri
commonli
use
vitro
bacteria
model
nonetheless
mimick
bacteri
infect
physiolog
relev
manner
prove
daunt
task
fact
still
lack
consensu
among
scientif
commun
assay
incorpor
sinc
exist
vitro
model
fail
recapitul
complex
microenviron
diseas
process
organ
level
expens
timeconsum
anim
test
often
implement
despit
low
predict
result
high
failur
rate
addit
vivo
model
although
physiolog
relev
suffer
interspeci
differ
put
question
amount
manner
bacteria
introduc
exampl
remain
signific
clinic
question
hospit
acquir
infect
recent
review
examin
differ
innat
immun
respons
reveal
compar
human
suffici
differ
organ
murin
immun
system
hinder
direct
translat
murin
experiment
data
human
patholog
event
despit
effort
bridg
gap
creat
human
mice
differ
exacerb
studi
bacteri
infect
pathogenesi
infect
often
result
lost
balanc
host
immun
respons
bacteri
overload
anoth
import
limit
use
vivo
model
lie
differ
pharmacokinet
profil
anim
model
occur
human
dramat
affect
drug
efficaci
addit
inher
differ
human
increas
use
anim
model
biomed
research
also
rais
concern
anim
welfar
relat
ethic
issu
grow
awar
anim
right
provid
impetu
recent
ban
test
finish
cosmet
product
cosmet
ingredi
anim
european
union
consequ
appropri
experiment
anim
model
vitro
model
abl
accur
predict
requir
drug
dose
drug
effici
human
use
complic
matter
widespread
use
biofilm
format
specif
even
qualifi
biofilm
mani
infect
chronic
infect
devic
associ
infect
particular
begin
pioneer
work
robert
koch
start
field
medic
bacteriolog
centuri
bacteria
larg
view
singl
freefloat
organ
refer
plankton
phenotyp
investig
bacteria
base
singlespeci
plankton
classif
enorm
success
led
golden
age
microbiolog
period
antimicrobi
abund
devast
human
pathogen
tuberculosi
diphtheria
discov
initi
acut
bacteri
infect
often
domin
plankton
bacteria
readili
cure
right
treatment
promptli
initi
first
observ
biofilm
aggreg
bacteria
enclos
within
matrix
extracellular
materi
report
lung
cystic
fibrosi
cf
patient
genet
disord
often
caus
repeat
lung
infect
decad
research
increasingli
awar
pathogen
bacteria
often
grow
structur
consortium
known
biofilm
attach
biotic
abiot
surfac
chronic
infect
bacteria
succeed
colon
form
matur
biofilm
within
human
host
infect
becom
phenotyp
physiolog
differ
plankton
counterpart
extrem
toler
innat
immun
system
antibiot
treatment
well
character
bacteria
biofilm
toler
time
higher
concentr
antibiot
plankton
bacteria
consequ
mani
biofilm
infect
develop
chronic
state
case
cf
chronic
biofilm
infect
persist
airway
patient
year
addit
resist
persist
incid
rate
biofilmrel
infect
also
extrem
high
difficult
precis
determin
gener
accept
human
bacteri
infect
biofilmrel
includ
chronic
wound
lungrel
infect
deviceassoci
infect
exampl
preval
sever
recent
survey
reveal
quarter
healthcareassoci
infect
hai
deviceassoci
involv
microorgan
form
biofilm
view
improv
understand
underli
caus
resist
persist
critic
need
better
manag
infect
involv
biofilm
toward
end
number
structur
biochem
characterist
biofilm
implic
increas
toler
vitro
vivo
model
system
one
primari
barrier
protect
underli
bacteria
host
immun
system
antimicrobi
sticki
matrix
extracellular
polymer
substanc
ep
consist
wide
varieti
protein
glycoprotein
glycolipid
extracellular
dna
encompass
bacteria
suggest
matrix
among
function
limit
access
antimicrobi
embed
bacteria
cell
either
physic
absorb
inactiv
compound
ep
compon
exampl
ampicillin
abl
penetr
wildtyp
k
pneumonia
biofilm
vitro
attribut
product
ampicillindegrad
enzym
interestingli
biofilm
form
mutant
k
pneumonia
also
resist
even
though
readili
penetr
ampicillin
suggest
resist
mechan
involv
inde
recent
evid
suggest
efflux
pump
system
also
play
import
role
resist
k
pneumonia
addit
target
antibiot
biofilm
also
capabl
compromis
host
innat
immun
respons
suppress
antimicrobi
activ
polymorphonuclear
leukocyt
pmn
vivo
case
biofilm
produc
opportunist
pathogen
pseudomona
aeruginosa
p
aeruginosa
commonli
observ
lung
cf
patient
suppress
pmn
suggest
quorumsens
qs
depend
mechan
bacteria
respond
fluctuat
cell
densiti
qsmediat
upregul
virul
factor
includ
rhamnolipid
abl
elimin
incom
pnm
contact
therebi
creat
shield
around
biofilm
bacteria
block
qs
either
mutat
administr
qs
inhibitori
drug
sensit
biofilm
bacteria
furthermor
presenc
multipl
bacteri
speci
phenotyp
divers
subpopul
within
biofilm
also
link
increas
toler
chronic
exampl
discov
presenc
haemophilu
influenza
within
polymicrobi
biofilm
promot
moraxella
catarrhali
resist
antibiot
host
clearanc
otiti
media
increas
resist
mediat
via
quorum
signal
depend
pathway
similarli
increas
effect
multibacteria
biofilm
support
mutualist
partnership
sreptococu
orali
actinomyc
naeslundii
form
dental
plaqu
scenario
coaggreg
bacteria
form
nutrit
benefici
environ
allow
bacteria
grow
neither
grew
absenc
final
phenotyp
diversif
bacteria
respons
steep
nutrient
gradient
vari
environment
stress
also
suggest
drive
infect
persist
one
classic
exampl
presenc
persist
cell
biofilm
subpopul
cell
slowgrow
growth
arrest
case
metabol
inact
antibiotictoler
persist
play
major
role
recalcitr
relaps
chronic
infect
addit
increas
toler
matur
biofilm
within
human
host
provid
bacteri
inoculum
opportun
spread
serv
reservoir
plasmid
carri
antibiot
resist
gene
collect
distinct
structur
biochem
characterist
biofilm
make
extrem
persist
difficult
treat
also
complic
diseas
model
use
either
vitro
vivo
model
system
vitro
model
often
lack
host
immun
compon
fail
recapitul
complex
physic
chemic
environ
bacteria
may
experi
vivo
establish
chronic
infect
model
anim
equal
challeng
date
pathogen
bacteria
studi
use
acut
infect
anim
model
involv
biofilm
reflect
chronic
state
infect
anoth
signific
challeng
establish
model
concern
amount
manner
bacteria
introduc
high
infect
dose
sometim
lethal
ethic
challeng
infect
lower
dose
often
resolv
rapidli
host
immun
system
result
great
inconsist
hand
anim
model
aim
model
chronic
bacteri
infect
involv
embed
bacteria
biofilmlik
matrix
agar
algin
prevent
host
clearanc
use
preform
biofilm
implant
nonetheless
embed
bacteria
polymer
matrix
produc
artifici
environ
inaccur
repres
flow
oxygen
nutrient
environ
vivo
sinc
preform
biofilm
vitro
differ
morpholog
physiolog
vivo
biofilm
discuss
detail
later
inaccur
mimicri
infecti
human
diseas
common
final
vivo
model
date
focu
monospeci
infect
accur
repres
infect
physiolog
condit
often
result
colon
one
microb
recent
studi
demonstr
p
aeruginosa
use
peptidoglycan
shed
gramposit
bacteria
stimul
product
multipl
lytic
factor
prokaryot
eukaryot
cell
coinfect
model
use
drosophila
murin
model
suggest
import
polymicrobi
interact
infect
resist
persist
light
necessari
develop
new
assay
model
simpli
yet
precis
replic
vivo
microenviron
reliabl
predict
record
tissu
activ
physiolog
patholog
condit
model
system
essenti
allow
mechanist
understand
dynam
interact
among
relev
factor
moreov
provid
better
predict
power
assess
clinic
translat
potenti
novel
antimicrobi
antimicrobi
materi
toward
end
multipl
vitro
ex
vivo
model
emerg
recent
year
review
highlight
recent
technolog
advanc
improv
model
relev
well
advantag
disadvantag
model
system
tabl
firm
understand
advantag
limit
hope
guid
us
select
appropri
system
probe
infect
mechan
effect
effici
manner
aim
better
understand
human
physiolog
patholog
cellular
level
subsequ
establish
better
represent
intercellular
extracellular
interact
inflammatori
respons
ultim
believ
use
advanc
vitro
vivo
model
safe
effect
therapeut
tabl
comparison
vitro
organoid
organonachip
ex
vivo
vivo
model
strategi
develop
address
antibiot
resist
crisi
global
scale
develop
vitro
model
bacteri
infect
biofilm
began
initi
observ
sessil
bacteria
recognit
role
human
chronic
infect
mani
vitro
model
sinc
emerg
design
mimic
biofilm
format
use
specif
bacteria
control
environ
although
often
regard
oversimplist
vitro
model
still
larg
use
today
indispens
mechanist
understand
biolog
bacteri
infect
biofilm
format
addit
role
elucid
underli
biolog
also
heavili
reli
upon
screen
tool
interrog
librari
antimicrobi
agent
current
drug
discoveri
paradigm
due
number
advantag
offer
low
cost
easi
setup
amen
highthroughput
design
autom
nonetheless
increas
awar
simplifi
vitro
model
often
fail
includ
import
environment
paramet
host
immun
system
mammalian
cell
therefor
may
lack
effect
predict
power
fact
mani
promis
antimicrobi
drug
fail
translat
bench
bedsid
partli
due
lack
vitro
model
effect
predict
longterm
antimicrobi
perform
vivo
regard
orthogon
assay
must
includ
rule
fals
posit
fals
neg
condit
extrem
caution
taken
interpret
result
obtain
vitro
model
gener
setup
advantag
limit
commonli
use
vitro
model
system
introduc
hope
serv
valuabl
guid
model
select
well
data
interpret
microtit
plate
mtp
base
system
among
commonli
use
biofilm
model
system
import
tool
studi
earli
stage
biofilm
format
system
biofilm
typic
grown
either
bottom
wall
microtit
plate
evalu
abil
antimicrobi
erad
biofilm
specif
surfac
materi
propens
resist
biofilm
format
biofilm
also
grown
surfac
coupon
place
well
plate
monitor
chang
biofilm
system
also
straightforward
biofilm
quantifi
chang
mass
use
stain
like
crystal
violet
safranin
congo
red
chang
metabol
activ
use
xtt
viabil
assay
exampl
mtpbase
system
util
investig
influenc
dnase
ca
extracellular
dna
biofilm
format
growth
biofilm
biomass
quantifi
use
crystal
violet
indic
enhanc
diminish
biofilm
growth
altern
combin
livedead
stain
confoc
laser
scan
microscopi
clsm
allow
visual
chang
bacteri
viabil
biofilm
morpholog
even
real
time
group
show
thick
staphylococcu
epidermidi
epidermidi
biofilm
could
form
mtp
success
appli
model
system
assess
abil
novel
superparamagnet
iron
oxid
nanoparticl
spion
encapsul
polymersom
erad
biofilm
combin
use
clsm
livedead
stain
reveal
dosedepend
bacteria
death
function
drug
spion
load
classic
mtpbase
system
howev
concern
portion
accumul
biomass
may
result
biofilm
form
process
rather
cell
sediment
subsequ
entrap
cell
sediment
within
ep
address
concern
variat
mtp
base
system
call
calgari
biofilm
devic
cbd
fig
introduc
biofilm
form
lid
peg
fit
well
microtit
plate
contain
bacteria
cbd
success
use
rapid
reproduc
assay
screen
biofilm
suscept
antibiot
instanc
gramneg
gramposit
pathogen
bacteria
variou
veterinari
sourc
could
readili
form
biofilm
cbd
deploy
determin
minimum
inhibitori
concentr
mic
minimum
biofilm
erad
concentr
mbec
wide
array
antibiot
recent
biofilm
form
escherichia
coli
ecoli
staphylococcu
aureu
saureu
cbd
exploit
tool
investig
role
carbon
sourc
glucos
mannitol
fructos
glycerol
etc
erad
biofilm
aminoglycosid
importantli
screen
result
obtain
cbdbase
biofilm
assay
success
translat
mous
chronic
urinari
tract
infect
model
combin
gentamicin
mannitol
result
almost
log
reduct
biofilm
viabil
suppress
spread
bacteri
infect
kidney
quantif
viabl
cell
biofilm
form
devic
typic
involv
bacteria
recoveri
use
sonic
howev
anywher
cell
may
disassoci
procedur
depend
protocol
follow
equip
use
result
data
discrep
subsequ
hinder
appropri
data
interpret
visual
biofilm
architectur
microscopi
method
scan
electron
microscopi
sem
clsm
also
challeng
requir
detach
peg
lid
use
plier
make
method
laborintens
amend
highthroughput
screen
addit
argu
physiolog
profil
detach
popul
may
repres
whole
popul
outermost
cell
tend
detach
first
cell
may
phenotyp
differ
attach
microtit
surfac
due
steep
gradient
nutrient
gase
studi
kinet
earli
stage
biofilm
format
particularli
initi
adhes
bacteria
earli
stage
biofilm
format
anoth
modifi
mtpbase
method
biofilm
ring
test
develop
base
abil
bacteria
immobil
magnet
bead
form
biofilm
kinet
biofilm
format
determin
measur
motil
magnet
bead
time
use
plate
reader
applic
biofilm
ring
test
rang
evalu
antibiot
suscept
biofilm
assess
biofilm
form
potenti
kinet
clinic
isol
also
use
studi
contribut
extracellular
polymer
substanc
ep
molecular
pathway
format
biofilm
comparison
standard
crystal
violet
stain
method
biofilm
ring
test
much
faster
reproduc
allow
highthroughput
screen
wash
stain
involv
worth
note
howev
biofilm
ring
test
limit
investig
earli
stage
biofilm
format
provid
inform
matur
biofilm
use
mtpbase
assay
offer
multitud
advantag
assay
fairli
cheap
special
equip
need
also
provid
opportun
multiplex
multipl
organ
treatment
incorpor
singl
run
ideal
identifi
potenti
antibiofilm
biomateri
pinpoint
gene
essenti
biofilm
surfac
attach
addit
cultur
condit
temperatur
oxygen
co
concentr
composit
growth
media
easili
manipul
investig
effect
environment
factor
biofilm
format
choic
system
use
realli
depend
question
one
want
answer
often
time
combin
differ
approach
requir
provid
complet
answer
nevertheless
mtpbase
system
close
system
static
condit
environ
includ
nutrient
avail
signal
molecul
etc
biofilm
form
chang
time
often
recapitul
vivo
condit
recent
transcriptom
analysi
suggest
biofilm
form
static
condit
differ
gene
express
pattern
form
flow
condit
prompt
develop
flowbas
system
mimic
fluid
flow
present
mani
vivo
scenario
cours
one
make
argument
noth
ever
static
human
bodi
yet
static
vitro
bacteria
cultur
commonplac
contrast
mtpbase
system
flowbas
system
modifi
robbin
devic
mrd
flow
cell
center
diseas
control
biofilm
reactor
drip
flow
reactor
rotat
disc
reactor
open
system
spent
medium
metabol
byproduct
dead
cell
remov
constantli
replac
fresh
medium
user
defin
speed
composit
use
flowbas
system
allow
format
matur
biofilm
addit
control
hydrodynam
condit
flow
paramet
shear
forc
modul
therefor
suitabl
investig
physic
resist
biofilm
similar
mtpbase
system
structur
physiolog
live
biofilm
monitor
noninvas
coupl
clsm
one
first
flow
system
modifi
robbin
devic
mrd
fig
consist
pipe
sever
thread
hole
coupon
locat
although
origin
design
monitor
biofilm
format
differ
flow
speed
complet
mix
tubular
recycl
reactor
sinc
adapt
studi
variou
aspect
biofilm
format
exampl
prove
particularli
use
evalu
effect
surfac
modif
biofilm
format
control
flow
condit
state
navaortiz
et
al
preirradi
glycidyl
methacryl
gma
graft
polyethylen
pe
polypropylen
pp
function
cyclodextrin
surfac
follow
studi
surfac
function
strategi
provid
pe
pp
opportun
incorpor
antifung
drug
miconazol
prevent
adhes
biofilm
format
candida
albican
medic
devic
made
polym
addit
mdr
effect
evalu
effect
antibiot
lock
therapi
catheterrel
biofilm
infect
could
accur
simul
fluid
dynam
biofilm
format
compar
static
microtit
plate
system
mrd
advantag
support
continu
biofilm
growth
matur
sever
week
howev
mrd
design
allow
direct
observ
quantif
biofilm
coupon
must
remov
devic
analysi
therefor
suffer
lower
throughput
allow
direct
inspect
biofilm
develop
sever
flow
cell
system
develop
commerci
avail
origin
flow
cell
system
consist
two
chamber
connect
beam
later
miniatur
includ
multipl
channel
combin
microscopi
method
system
allow
realtim
nondestruct
record
structur
dynam
biofilm
develop
help
allow
scientist
monitor
earliest
stage
bacteri
surfac
attach
therefor
gain
better
understand
process
contribut
bacteri
colon
biofilm
format
recent
multispeci
biofilm
model
consist
four
oral
bacteri
speci
also
establish
flow
cell
studi
periimpl
infect
biofilm
polymicrobi
natur
could
extrem
help
build
realist
biofilm
model
vitro
also
elucid
role
multispeci
interact
biofilm
colon
similar
mrd
howev
system
rel
lowthroughput
compar
mtpbase
system
addit
geometri
flow
cell
system
care
design
critic
affect
uniform
flow
region
determin
valid
system
evalu
bacteri
adhes
biofilm
format
c
cdc
biofilm
reactor
schemat
diagram
drip
flow
reactor
variou
compon
e
schemat
diagram
constant
depth
film
ferment
cdff
closeup
view
scraper
blade
slide
biofilm
maintain
constant
depth
biofilm
thick
exce
thick
well
final
air
bubbl
frequent
form
system
chang
temperatur
pressur
lead
destruct
develop
biofilm
consist
result
learn
renal
dialysi
process
recent
studi
propos
modif
flow
cell
system
could
potenti
minim
bubbl
format
center
diseas
control
cdc
biofilm
reactor
fig
anoth
exampl
commerci
avail
flow
system
onelit
vessel
polyethylen
top
support
eight
independ
rod
hous
total
remov
coupon
customiz
materi
reactor
magnet
stir
bar
middl
devic
rotat
appli
constant
high
shear
aforement
coupon
adjust
alter
rotat
speed
independ
feed
rate
allow
simultan
investig
effect
shear
stress
medium
composit
biofilm
format
compar
mdr
flow
cell
anoth
advantag
cdc
biofilm
reactor
biofilm
grown
reproduc
much
higher
shear
stress
result
recogn
astm
intern
standard
method
quantif
p
aeruginosa
biofilm
grown
high
shear
continu
flow
unfortun
cdc
biofilm
reactor
share
common
disadvantag
mrd
flow
cell
system
low
throughput
individu
coupon
taken
predetermin
time
point
analysi
effort
made
creat
inonlin
monitor
system
rapid
accur
detect
bacteri
attach
growth
real
time
instanc
labelfre
interdigit
microelectrod
biosensor
integr
implant
devic
imped
character
epidermidi
biofilm
develop
devic
allow
monitor
bacteri
growth
earli
hour
inocul
high
effect
techniqu
sinc
extend
petri
dish
plate
nonetheless
method
detect
provid
inform
biofilm
structur
physiolog
addit
larg
volum
reactor
make
less
appeal
screen
antimicrobi
especi
surfaceteth
larg
amount
materi
need
final
semiopen
design
reactor
make
prone
contamin
special
vitro
biofilm
model
system
also
develop
investig
effect
certain
paramet
biofilm
format
exampl
drip
flow
reactor
fig
design
investig
biofilm
format
low
shear
condit
airliquid
interfac
studi
biofilm
vertic
heterogen
incorpor
microelectrod
sensor
biofilm
cultur
drip
flow
condit
also
use
studi
mass
transport
chemic
gradient
within
biofilm
anoth
custom
biofilm
model
constant
depth
film
ferment
cdff
fig
allow
growth
biofilm
welldefin
thick
within
system
biofilm
grown
bottom
well
set
depth
scraper
blade
remov
anyth
well
particularli
use
studi
effect
biofilm
thick
antimicrobi
penetr
system
incorpor
vari
flow
condit
eg
high
vs
low
shear
maintain
rel
stabl
nutrient
concentr
time
allow
biofilm
matur
vitro
flow
system
less
adapt
highthroughput
analysi
laborintens
often
requir
special
equip
biofilm
form
surfac
throughout
model
system
except
drip
flow
reactor
isol
compart
singl
bacteria
speci
singl
combin
test
per
run
furthermor
aspect
vivo
environ
host
immun
system
still
miss
system
addit
individu
advantag
disadvantag
mtpbase
flowbas
system
share
sever
common
limit
one
pitfal
design
vitro
biofilm
model
mimic
vivo
environ
lie
use
irrelev
bacteri
strain
lack
knowledg
diseaserel
microbi
consortia
interact
healthi
pathogen
strain
least
part
blame
low
translat
rate
vitro
vivo
studi
even
adequ
inform
avail
variou
bacteri
strain
yet
cultiv
model
absenc
appropri
formul
diseaserel
growth
media
impos
challeng
establish
repres
vitro
model
system
biofilm
vivo
often
grow
nutrient
ga
defici
environ
defici
may
differenti
gene
express
addit
differ
nutrient
composit
lead
alter
biofilm
format
virul
shown
p
aeruginosa
sens
use
artifici
growth
media
rich
nutrient
may
lead
clinic
irrelev
phenotyp
consequ
effort
better
repres
vivo
condit
rang
artifici
medium
custom
particular
diseas
use
patientderiv
biolog
fluid
exampl
use
synthet
cf
sputum
medium
result
similar
vitro
gene
express
profil
observ
expector
cf
sputum
final
hostor
host
tissuerel
factor
also
miss
aforement
vitro
biofilm
model
includ
lack
host
tissu
structur
exclus
host
cell
particularli
immun
cell
paramet
alter
nutrient
ga
distribut
abund
therefor
implic
inclus
futur
model
although
mtpbase
system
flowbas
system
clear
limit
util
vitro
biofilm
research
decad
contribut
tremend
understand
biofilm
biolog
abil
adjust
individu
variabl
maintain
experiment
paramet
produc
welldefin
environ
effect
singl
element
biofilm
develop
system
studi
howev
must
recogn
reductionist
approach
limit
vivo
environ
except
complex
choos
vitro
model
import
realiz
singl
biofilm
model
system
better
model
limit
factor
howev
specif
model
may
appropri
base
question
investig
clinic
relev
model
exampl
mtpbase
system
wellsuit
highthroughput
screen
larg
number
variabl
investig
librari
compound
test
investig
process
involv
initi
bacteri
attach
flow
cell
system
incorpor
fluid
flow
provid
opportun
realtim
observ
use
microscopi
method
drip
flow
system
prefer
studi
biofilm
heterogen
cdc
biofilm
reactor
prove
effect
assess
biofilm
format
biolog
relev
materi
evalu
effect
surfac
modif
biofilm
format
hallmark
vivo
biofilm
includ
aggreg
bacteria
enclos
matrix
extracellular
materi
extrem
toler
host
immun
system
antibiot
treatment
format
matur
dispers
biofilm
result
dynam
interact
complex
bacteria
commun
host
environ
hard
mimic
despit
continu
effort
optim
simpl
vitro
system
emerg
evid
shown
signific
differ
exist
vitro
vivo
biofilm
one
strike
differ
lie
size
biofilm
recent
survey
biofilm
size
vivo
reveal
biofilm
approxim
diamet
rang
occur
presenc
abiot
surfac
implant
howev
even
surfaceassoci
biofilm
least
two
order
magnitud
smaller
biofilm
observ
vitro
rang
cm
mtp
base
system
cm
flowbas
system
addit
size
differ
shape
biofilm
also
differ
case
p
aeruginosa
opportunist
pathogen
commonli
involv
cf
classic
mushroom
structur
found
vitro
yet
observ
vivo
chang
morpholog
biofilm
vivo
fulli
understood
like
due
combin
nutrientoxygen
deplet
presenc
host
immun
system
eg
pmn
particular
host
immun
compon
typic
miss
almost
vitro
model
system
one
classic
exampl
highlight
import
role
host
immun
respons
biofilm
format
come
studi
investig
p
aeruginosa
biofilm
format
lung
cf
patient
use
specif
p
aeruginosa
pna
fluoresc
situ
hybrid
probe
biofilm
observ
aggreg
structur
surround
pronounc
pmn
inflamm
respiratori
zone
confirm
observ
bacteria
immun
cell
interact
also
demonstr
vitro
vivo
mous
model
addit
direct
bactericid
activ
via
phagocytosi
immun
cell
also
regul
biofilm
format
growth
oxygen
nutrient
consumpt
consequ
heterogen
growth
pattern
vivo
biofilm
link
local
concentr
pmn
anoth
import
discrep
vitro
vivo
biofilm
multispeci
bacteri
commun
often
present
vivo
vitro
model
system
includ
one
strain
bacteria
studi
examin
bacteriolog
diabet
foot
wound
presenc
two
bacteri
isol
identifi
wound
anoth
exampl
oral
speci
bacteria
identifi
earli
dental
biofilm
healthi
human
subject
streptococci
abund
speci
although
much
known
interspeci
interact
polymicrobi
biofilm
format
begun
appreci
import
interact
alter
biofilm
virul
persist
detail
understand
role
polymicrobi
interact
human
infect
potenti
prevent
cur
strategi
diseas
refer
reader
comprehens
review
peter
colleagu
factor
may
also
contribut
differ
seen
vitro
vivo
biofilm
includ
complex
chemic
landscap
biofilm
encount
vivo
vari
biofilm
durat
chronic
infect
vivo
last
much
longer
lack
abiot
surfac
vivo
infect
except
deviceassoci
infect
due
glare
discrep
unclear
whether
vitro
biofilm
suffici
repres
vivo
biofilm
whether
result
obtain
vitro
system
translat
drug
develop
perspect
differ
least
part
mitig
take
advantag
sophist
organoid
andor
organonachip
platform
describ
next
vitro
organoid
microfluid
model
histori
term
organoid
trace
back
henri
van
peter
wilson
univers
north
carolina
chapel
hill
propos
dissoci
individu
silica
spong
cell
could
selforgan
regener
whole
function
organ
sinc
numer
cultur
method
develop
util
gener
organoid
variou
origin
typic
organoid
vitro
model
cultur
matrigel
gellik
scaffold
materi
mimic
extracellular
matrix
ecm
environ
provid
essenti
growth
cue
organoid
cultur
distinguish
immort
cell
line
cultur
organoid
abl
maintain
cellular
heterogen
exhibit
organlik
function
similar
target
host
tissu
longterm
cultur
condit
date
organotyp
cultur
includ
cultur
deriv
either
pluripot
stem
cell
psc
adult
stem
cell
asc
wide
appli
tissu
engin
drug
deliveri
incorpor
stem
cell
organoid
first
develop
japanes
research
sasai
demonstr
cerebr
cortex
tissu
could
gener
embryon
stem
cell
esc
use
effici
aggreg
cultur
sfebq
method
later
sato
colleagu
gener
intestin
organoid
adult
singl
stem
cell
cultur
matrigel
subsequ
develop
new
method
rspondin
method
employ
growth
factor
induc
key
endogen
nich
signal
eventu
develop
human
intestin
organoid
organ
harbor
stem
cell
gener
esc
induc
pluripot
stem
cell
ipsc
selforgan
cultur
mainli
employ
develop
organoid
due
selfrenew
differenti
capabl
hand
asc
primari
cellderiv
organoid
capabl
develop
matur
phenotyp
compar
ipsc
therefor
also
appli
mani
model
includ
gastrointestin
lung
liver
organoid
instanc
gastrointestin
infect
one
investig
diseas
model
sever
organoid
model
describ
recent
year
use
cryptderiv
mous
intestin
organoid
zhang
et
al
investig
pathophysiolog
interact
salmonella
epitheli
cell
visual
postinfect
morpholog
chang
organoid
immunofluoresc
disrupt
salmonella
infect
organoid
observ
addit
compar
level
express
tight
junction
protein
occludin
nfkb
pathway
infect
organoid
noninfect
control
group
discov
salmonella
infect
induc
disrupt
epitheli
tight
junction
activ
inflamm
pathway
infect
organoid
importantli
salmonellahost
interact
vitro
recapitul
mani
characterist
observ
vivo
salmonellacol
anim
model
includ
bacteri
invas
tight
junction
disrupt
host
inflammatori
respons
organoid
model
gener
either
gastric
primari
cell
gastric
epitheli
stem
cell
also
use
studi
host
respons
helicobact
pylori
infect
one
main
risk
gastric
adenocarcinoma
caus
number
gastric
diseas
one
exampl
human
gastric
primari
cell
use
investig
helicobact
pylori
infect
mechan
tumorigenesi
primari
cell
isol
healthi
human
gastric
gland
grown
matrigel
contain
defin
growth
factor
development
regul
apoptosi
inhibitor
differenti
spheroid
gastric
organoid
observ
withdrawn
medium
confirm
downregul
stem
cell
marker
eg
upregul
gastric
differenti
marker
eg
activ
replic
cultur
transfer
environ
allow
easier
manipul
experiment
condit
interestingli
import
characterist
fulli
function
gastric
epithelium
well
polar
cell
presenc
tight
junction
marker
differenti
gene
express
pattern
maintain
even
cultur
confirm
microarray
immunofluoresc
expos
gastric
pathogen
h
pylori
infect
primari
cell
exhibit
hallmark
bacteri
infect
upregul
signal
pathway
indic
activ
host
respons
importantli
use
primari
untransform
cell
instead
commonli
use
gastric
adenocarcinomaderiv
cell
line
organoid
demonstr
similar
hostbacteria
interact
observ
vivo
may
indic
may
serv
better
model
studi
h
pylori
infect
includ
may
lead
gastric
diseas
even
gastric
adenocarcinoma
anoth
gastrointestin
organoid
system
studi
h
pylori
infect
involv
use
gastric
epitheli
stem
cell
organoid
system
gastric
epitheli
stem
cell
differenti
four
lineag
exhibit
repetit
structur
gland
pit
domain
wnt
suggest
import
regul
stem
cell
differenti
wnt
silenc
gastric
epitheli
stem
cell
differenti
toward
pit
gland
lineag
monitor
express
cytokin
mrna
found
cell
gland
region
stronger
inflammatori
respons
h
pylori
infect
robust
nfkb
activ
compar
pit
lineag
although
still
earli
stage
organoid
model
clearli
demonstr
potenti
establish
patient
specif
diseas
model
studi
h
pylori
infect
gastric
patholog
recent
organoid
complic
tissu
brain
gener
use
human
pluripot
stem
cell
grown
agit
matrigel
substrat
follow
similar
protocol
sever
diseas
model
gener
studi
cancer
well
mani
infecti
diseas
bacteri
viral
origin
allow
examin
host
respons
cellmicroorgan
interact
instanc
organoid
use
studi
viral
infect
zika
viru
infect
zikv
brain
organoid
develop
use
ipsc
zikv
outbreak
deriv
embryoid
bodi
neuroectoderm
tissu
embed
matrigel
scaffold
transfer
spin
bioreactor
nutrient
absorpt
tissu
growth
report
cultur
protocol
result
rapid
yet
comprehens
develop
brain
tissu
variou
discret
interdepend
brain
region
observ
subsequ
experi
investig
impact
zikv
infect
establish
brain
organoid
use
immunocytochemistri
electron
microscopi
conclud
zikv
target
human
brain
cortic
progenitor
cell
lead
reduc
brain
cell
viabil
elev
cell
apoptosi
autophagi
ultim
interfer
neurogenesi
neurodevelop
take
advantag
improv
tissu
organ
integr
organoid
model
gain
wide
attent
surmount
mani
limit
present
convent
model
includ
insuffici
replic
organ
structur
microenviron
nevertheless
organoid
capabl
replic
organ
structur
mimick
physiolog
function
vitro
integr
reconstitut
featur
tissuetissu
interfac
chemic
gradient
biomechan
cue
provid
surround
microenviron
remain
signific
challeng
address
issu
microfabr
microfluid
techniqu
emerg
leverag
better
recapitul
microenviron
live
organ
incorpor
cellcel
interact
chemic
biomechan
cue
consequ
microengin
biomimet
model
may
accur
represent
whole
human
organ
provid
valuabl
inform
effici
guid
design
execut
subsequ
vivo
studi
short
organonachip
system
function
microchip
hous
live
cell
mimic
structur
function
human
organ
organonachip
system
often
fabric
pdm
biodegrad
poli
dllactidecoglycolid
plga
use
techniqu
replica
model
soft
lithographi
microcontact
print
recent
microfabr
techniqu
greatli
benefit
develop
integr
circuit
technolog
wafer
fabric
facil
electr
engin
mani
challeng
face
organonachip
system
miniatur
reproduct
complex
architectur
similar
human
tissu
address
order
mimic
vivo
microenviron
highest
extent
use
biomateri
fabric
organonachip
system
provid
opportun
allow
higher
precis
accuraci
instanc
sudo
et
al
implement
microfluid
platform
incorpor
typei
collagen
gel
scaffold
two
microfluid
channel
static
flow
condit
cocultur
hepatocyt
vascular
cell
sidewal
collagen
scaffold
vascular
liver
tissu
cultur
microenviron
observ
later
pioneer
studi
advanc
microfabr
technolog
incorpor
biolog
mechan
cue
exampl
first
human
lungonachip
develop
biomimet
microfluid
system
reconstitut
critic
function
human
alveolarcapillari
interfac
especi
mechan
strain
present
vivo
addit
hollow
b
liveronachip
devic
c
skinonachip
devic
separ
channel
vertic
stack
cell
layer
bbbonachip
devic
variou
brain
tissu
cell
cocultur
e
kidneyonachip
devic
f
gutonachip
devic
vacuum
chamber
builtin
mimic
intestin
movement
vacuum
chamber
specif
induc
lunglik
stretch
epitheli
endotheli
layer
fig
sinc
mani
organonachip
model
includ
liveronchip
skinonchip
intestineonchip
bloodbrainbarri
bbb
onchip
kidneyonchip
devic
emerg
fig
follow
bottomup
revers
engin
approach
tissuetissu
interfac
biochem
andor
neuroelectr
cue
characterist
mechan
forc
artifici
introduc
provid
organspecif
physic
microenviron
organonachip
system
provid
promis
platform
model
physiolog
patholog
function
tissu
organ
vitro
adapt
area
antitumor
drug
deliveri
organ
function
mimicri
membranebas
permeabl
toxicolog
investig
exhibit
great
potenti
investig
cellular
mechan
organ
physiolog
addit
applic
organonachip
system
also
use
studi
bacteri
viral
infect
vitro
use
aforement
lungonachip
model
organonachip
model
use
studi
innat
cellular
respons
pulmonari
infect
e
coli
green
fluoresc
protein
gfp
modifi
e
coli
introduc
activ
human
alveolar
epitheli
cell
five
hour
upper
side
pdm
membran
five
hour
incub
presenc
fluorescentlabel
neutrophil
indic
activ
human
pulmonari
microvascular
endotheli
cell
assess
result
show
bacteria
clear
neutrophil
indic
biomimet
microchip
effect
replic
well
record
gener
immun
respons
microbi
infect
human
lung
alveoli
cellular
level
anoth
lungonachip
technolog
investig
cell
recruit
migrat
infect
immun
respons
instead
introduc
proinflammatori
mediat
tumor
necrosi
directli
ad
system
replic
live
cellproduc
immun
respons
close
mimic
vivo
condit
regard
tcell
hybridoma
macrophag
immort
dendrit
cell
mycobacterium
avium
express
cfp
first
separ
load
microdevic
longterm
cell
behavior
subsequ
imag
real
time
investig
cell
behavior
inflammatori
chemokin
gradient
lp
immunogen
peptideload
macrophag
mix
iabpeptid
restrict
cell
introduc
infect
compart
wherea
cell
load
migratori
compart
although
movement
cell
signific
realtim
imag
demonstr
migrat
recruit
kinet
cell
toward
infect
site
h
initi
load
cell
addit
primari
dendrit
cell
also
investig
regard
migrat
toward
load
chemoattract
cellinduc
gradient
cytokin
chemokin
direct
migrat
matur
dendrit
cell
observ
load
activ
compart
similarli
long
last
direct
movement
immatur
dendrit
cell
toward
activ
compart
contain
cocultur
proinflammatori
nonactiv
matur
dendrit
cell
cell
observ
demonstr
chemotact
properti
devic
although
bacteria
directli
involv
studi
devic
potenti
promis
platform
studi
host
immun
respons
infect
lung
two
year
gener
lungonachip
ingber
et
al
also
demonstr
anoth
microfluid
devic
gutonachip
similar
design
previou
lungonachip
devic
biomimet
gutonachip
consist
two
microfluid
channel
separ
layer
human
intestin
epitheli
cell
grown
porou
pdm
membran
coat
ecm
protein
system
similarli
contain
two
vacuum
control
built
side
channel
mimic
complex
physiolog
peristalt
motion
live
intestin
exert
cyclic
strain
hz
importantli
addit
cell
common
intestin
microb
lactobacillu
rhamnosu
gg
lgg
cocultur
epithelium
one
week
first
time
ever
monitor
transepitheli
amonipeptidas
lgg
bgalactosidas
activ
cell
morpholog
integr
viabil
intestin
epitheli
cell
monolay
confirm
interestingli
compar
cell
grown
either
static
transwel
chamber
flow
microfluid
chip
without
cyclic
strain
cell
expos
cyclic
strain
increas
height
polar
day
tend
spontan
form
undul
fold
moreov
accord
transendotheli
electr
resist
teer
result
cocultur
probiot
strain
bacteria
affect
intestin
epitheli
integr
intestin
barrier
function
enhanc
although
origin
gutonachip
employ
studi
bacteri
infect
set
foundat
cocultur
cell
bacteria
strain
analyz
biolog
mechan
condit
inflammatori
cell
microbiom
infect
recent
studi
group
leverag
cocultur
microchip
model
human
intestin
investig
probiot
antibiot
suppress
villu
injuri
induc
pathogen
bacteria
furthermor
studi
immun
cell
specif
inflammatori
cytokin
peristalsislik
motion
impact
intestin
inflamm
integr
epitheli
barrier
function
inflammatori
bowel
diseas
studi
sever
differ
factor
affect
normal
intestin
function
commens
e
coli
microb
lipopolysaccharid
endotoxin
lp
peripher
blood
mononuclear
cell
pbmc
taken
consider
investig
instanc
studi
reveal
enteroinvas
e
coli
eiec
would
rapidli
overgrow
apic
surfac
villi
within
h
induc
loss
normal
intestin
villu
morpholog
intestin
barrier
function
contrast
nonpathogen
laboratori
strain
e
coli
lipopolysaccharid
endotoxin
lp
alter
teer
valu
intestin
barrier
system
addit
although
introduc
pbmc
alon
induc
damag
intestin
model
combin
nonpathogen
e
coli
lp
reveal
signific
loss
intestin
barrier
function
factor
inflammatori
cytokin
eg
antiinflammatori
probiot
vsl
cyclic
strain
also
evalu
result
reveal
cyclic
stress
mimic
physiolog
peristalsislik
mechan
motion
antiinflammatori
probiot
promot
intestin
function
indic
increas
teer
valu
decreas
colon
bacteria
howev
inflammatori
cytokin
impact
intestin
model
even
presenc
immun
cell
critic
microfluid
complex
provid
platform
analyz
interact
multipl
key
factor
includ
normal
tissu
cell
immun
cell
pathogen
nonpathogen
bacteria
lp
cytokin
separ
combin
fashion
consequ
vitro
model
serv
promis
platform
studi
gain
insight
human
patholog
physiolog
anoth
fundament
studi
investig
effect
enterohemorrhag
e
coli
ehec
colon
gi
tract
commens
microenviron
cocultur
microfluid
model
develop
use
hela
cell
commens
e
coli
biofilm
fig
introduc
ehec
establish
commens
environ
demonstr
pathogen
colon
strongli
impact
signal
molecul
present
commens
microenviron
experi
wildtyp
commens
e
coli
e
coli
strain
produc
indol
signal
molecul
inhibit
ehec
attach
cocultur
hela
cell
respect
follow
exposur
ehec
infect
compar
local
exposur
preindoletr
ehec
bacteria
determin
local
exposur
ehec
bacteria
commens
biofilm
effect
possibl
bacteri
signal
infect
andor
higher
concentr
indol
secret
local
commens
bacteria
data
provid
possibl
screen
differ
gi
microenviron
signal
pathogen
infect
well
select
potenti
probiot
strain
attenu
gi
bacteri
infect
largest
organ
human
bodi
skin
play
critic
role
wound
heal
assess
drug
bioavail
absorpt
tradit
monolay
skin
equival
use
studi
process
often
fail
mimic
normal
human
skin
barrier
function
properti
due
exclud
cell
type
improp
forc
applic
therebi
limit
physiolog
relev
improv
tradit
monolay
skin
equival
human
skin
equival
better
recapitul
natur
skin
tissu
composit
function
combin
endotheli
cell
adipos
tissu
immun
cell
ad
fullthick
skin
model
exampl
bella
et
al
introduc
fullthick
skinequival
vitro
model
use
silk
collagen
scaffold
combin
vascular
adipos
tissu
cultur
collagen
gel
engin
epidermalderm
tissu
cultur
silk
scaffold
propos
trilay
tissu
construct
express
physiolog
morpholog
epidermi
dermi
henc
establish
physiolog
relev
skinequival
vitro
model
howev
system
complic
produc
might
high
variabl
result
inconsist
result
skinonachip
system
develop
address
issu
establish
one
essenti
organonachip
system
ideal
reconstruct
human
skin
equival
multilay
engin
airliquid
interfac
expos
topic
stratum
corneum
layer
air
immers
dermal
layer
vasculatur
medium
among
sever
skinonachip
system
report
recent
year
ramadan
et
al
introduc
miniatur
skinonachip
model
cocultur
immort
human
keratinocyt
hacat
human
leukem
monocyt
lymphoma
cell
line
studi
aim
investig
effect
chemic
physic
stimul
bacteri
lp
function
integr
skin
barrier
compar
static
model
dynam
media
perfus
combin
airliquid
interfac
significantli
improv
tight
junction
format
extend
cell
viabil
day
compar
express
introduc
lp
cocultur
monocultur
result
also
show
keratinocyt
form
robust
barrier
protect
cell
lp
invas
anoth
skinonachip
model
develop
wufuer
et
al
simul
inflamm
edema
drug
absorpt
vitro
propos
model
consist
epiderm
keratinocyt
fibroblast
endotheli
cell
layer
introduc
variou
dose
perfus
fibroblast
channel
develop
onachip
skin
inflamm
model
analyz
express
proinflammatori
factor
result
confirm
patholog
mechan
inflamm
nfkb
signal
pathway
thu
demonstr
potenti
appli
skinonachip
equival
construct
vitro
skin
diseas
model
test
toxic
pharmaceut
agent
although
skinonachip
model
extens
use
toxicolog
pharmacolog
regen
applic
studi
investig
microb
biofilm
implic
acut
chronic
infect
delay
woundheal
process
induc
inflamm
sinc
acut
wound
chronic
skin
ulcer
disrupt
physic
chemic
barrier
skin
provid
ideal
grow
environ
microb
therefor
addit
skin
inflamm
cytotox
studi
devic
also
serv
novel
system
better
understand
mechan
wound
infect
wound
heal
well
test
biocompat
efficaci
antibiot
use
treat
wound
infect
regard
microfluid
wound
model
establish
test
mechanobiolog
structur
wound
environ
well
behavior
bacteriabiofilm
antibiot
treatment
one
studi
vitro
microfluid
wound
model
develop
examin
effect
dispersinb
gentamycin
methicillinresist
staphylococcu
pseudintermediu
mrsp
bacteri
biofilm
yshape
collagen
coat
microfluid
channel
serv
anim
wound
vitro
bacteria
label
fluoresc
dye
allow
direct
observ
imag
analysi
sampl
collect
outlet
show
higher
fluoresc
intens
mrsp
biofilm
remov
dispersinbgentamycin
addit
similar
devic
report
studi
growth
detach
epidermidi
biofilm
schemat
multiorgansonachip
cultur
liver
tumor
marrow
e
schemat
multiorganonachip
cultur
liver
heart
lung
tissu
f
view
microfluid
fourorganchip
devic
cultur
intestin
liver
skin
kidney
equival
g
gene
express
cocultur
fourorganchip
day
interpret
refer
color
figur
legend
reader
refer
web
version
articl
dispersin
b
rifampicin
treatment
bacteria
releas
upon
treatment
collect
quantifi
coloni
count
assay
result
prove
combin
deliveri
dispersinb
rifampicin
effect
remov
biofilm
form
epidermidi
bacteri
dispers
detect
end
treatment
despit
fact
skinonachip
system
contribut
significantli
skin
regener
drug
permeabl
test
applic
system
skin
infect
model
still
limit
therefor
requir
develop
moreov
current
skin
wound
infect
model
static
vitro
model
dynam
interact
bacteria
host
cell
woundheal
process
remain
unclear
advanc
novel
biomateri
microfluid
system
new
approach
bioprint
technolog
potenti
appli
fabric
skinonachip
system
ecm
embed
spatial
heterogen
incorpor
may
facilit
develop
repres
microfluid
skin
diseas
model
futur
deliv
pharmaceut
agent
brain
one
intens
investig
topic
recent
year
bbb
form
mainli
endotheli
cell
maintain
integr
homeostasi
central
nervou
system
cn
yet
inhibit
effici
drug
deliveri
sinc
free
diffus
substanc
circul
blood
brain
parenchyma
highli
restrict
still
bbb
identifi
main
target
brain
drug
deliveri
drug
deliveri
cn
requir
transport
across
bbb
mani
vitro
bbb
model
includ
bbbonachip
model
develop
character
drug
permeabl
intercellular
signal
mediat
neuroinflamm
mechan
brain
tumor
develop
brain
infect
exampl
one
studi
conduct
eugenin
et
al
examin
role
human
immunodefici
viru
hiv
infect
astrocyt
bbb
disrupt
use
transwel
model
anoth
studi
describ
cut
et
al
examin
select
autophagi
activ
host
defens
bbb
penetr
group
b
streptococcu
gb
one
lead
mening
pathogen
model
vivo
howev
although
mani
studi
carri
use
differ
vitro
bbb
model
studi
use
advantag
technolog
brain
infect
studi
one
underli
reason
limit
use
area
may
due
toxic
result
cocultur
brain
endotheli
cell
infecti
pathogen
brown
et
al
introduc
bbbonachip
microfluid
devic
consist
separ
vascular
brain
channel
separ
porou
pdm
membran
enabl
celltocel
interact
brain
tissu
cell
also
allow
independ
perfus
compart
followup
studi
report
group
cocultur
primari
human
brainderiv
microvascular
endotheli
cell
hbmvec
human
induc
pluripot
stem
cell
hipsc
deriv
human
cortic
neuron
pericyt
astrocyt
mimic
neurovascular
unit
stimul
bbb
model
lp
cytokin
solut
contain
author
examin
teer
valu
tight
junction
integr
metabolit
gener
prepar
data
suggest
bbb
integr
initi
disrupt
lp
indic
reduc
tight
junction
format
increas
membran
permeabl
recov
though
fulli
preexposur
level
timeand
lp
dosedepend
manner
addit
metabolit
obtain
channel
predict
metabol
network
activ
use
biolog
driven
comput
analysi
compar
pathway
activ
brain
vasculatur
result
suggest
use
differ
proteom
metabol
pathway
induc
inflamm
moreov
circumst
pathway
involv
vasculatur
remain
proinflammatori
state
wherea
part
bbb
start
rebound
cell
viabil
maintain
microchannel
microfluid
devic
allow
vitro
investig
tissu
organ
function
respons
variou
stimuli
henc
may
serv
suitabl
model
use
studi
incorpor
normal
tissu
cell
environment
toxin
pathogen
provid
better
understand
mechan
action
besid
organonachip
system
microfluid
system
develop
order
investig
bacteria
behavior
within
natur
habitat
biofilm
one
studi
investig
biofilm
morpholog
microfluid
system
mimic
natur
habitat
sequenc
corner
caus
biofilm
streamer
constant
flow
p
aeruginosa
use
porou
materi
made
transpar
nafion
microfluid
system
serv
artifici
soil
flow
soillik
porou
materi
p
aeruginosa
biofilm
tend
form
streamer
result
caus
rapid
clog
disrupt
constant
flow
studi
also
investig
effect
gene
express
profil
format
biofilm
streamer
instanc
defici
ep
matrix
product
produc
signific
biofilm
nonmotil
flagellar
mutant
produc
biofilm
streamer
similar
wild
type
addit
infect
bacteria
origin
viral
infect
h
hepat
b
viru
hbv
anoth
major
health
concern
today
toward
end
microfluid
primari
human
hepatocyt
phh
cultur
develop
physiolog
relev
preclin
platform
studi
hbv
infect
notabl
wellestablish
microfluid
system
abl
recapitul
hepat
sinusoid
microarchitectur
includ
function
bile
canaliculi
complet
cell
polar
extend
cultur
period
least
week
importantli
cultur
system
close
mimick
hbv
infect
process
vivo
infect
patientderiv
hbv
includ
hbv
replic
suppress
type
iii
ifn
isg
express
innat
immun
respons
plu
mainten
hbv
coval
close
circular
dna
cccdna
develop
liveronachip
microfluid
system
provid
way
expand
platform
organonachip
model
studi
hbv
viru
infect
pathogen
microbi
infect
well
previous
describ
microfluid
devic
focu
tissu
infect
inflamm
anoth
import
applic
organonachip
system
recapitul
cancer
growth
monitor
therapeut
respons
gener
microfluid
model
blood
vessel
system
tumor
blood
vessel
employ
assess
nanocarri
function
screen
drug
candid
seek
new
opportun
cancer
treatment
date
sever
type
vitro
tumoronachip
model
establish
effort
elucid
tumormicrovascular
interact
mimick
tumor
microenviron
one
studi
employ
previous
describ
organonachip
technolog
recapitul
investig
human
nonsmallcel
lung
cancer
nsclc
growth
invas
pattern
well
tumor
cell
respons
therapeut
cue
associ
breath
motion
addit
singl
organonachip
multiorgansonachip
also
known
bodyonachip
develop
understand
physiolog
coupl
differ
organ
vitro
studi
drug
metabol
gener
pharmacokinet
pk
pharmacodynam
pd
model
fig
e
one
studi
integr
micro
cell
cultur
analog
cca
system
fluoresc
oxygen
sens
system
mathemat
analyz
adsorpt
distribut
metabol
elimin
toxic
admet
chemic
vitro
recent
capabl
multiorgansonachip
extend
analyz
physiolog
coupl
differ
organ
system
admet
profil
vitro
drug
candid
test
exampl
intestin
skin
liver
kidney
cell
cocultur
chip
interconnect
fluidic
environ
enabl
reproduc
tissu
cultur
day
fig
g
best
mimic
vivo
condit
pharmaceut
agent
first
administ
intestin
tissu
isol
medium
reservoir
subsequ
distribut
drug
carri
circul
medium
liver
tissu
mimic
firstpass
metabol
final
secondari
metabol
final
excret
drug
success
execut
kidney
equival
altogeth
link
fourorganonachip
system
provid
thorough
evalu
physiolog
homeostasi
barrier
integr
molecular
transport
pharmacokinet
pharmacodynam
paramet
toxic
toler
dose
time
cours
drug
candid
consequ
propos
studi
provid
potenti
platform
futur
investig
antiinflamm
antiinfect
drug
respons
nevertheless
although
organonachip
system
show
promis
futur
exhibit
sever
share
limit
requir
attent
one
frequent
question
ask
novel
techniqu
vitro
model
accur
mimic
anim
human
vivo
system
first
technic
point
view
improv
microfabr
method
futur
advanc
microchip
improv
effici
valid
organonachip
system
studi
conduct
show
organonachip
match
vivo
respons
although
pdm
common
organonachip
materi
suitabl
materi
due
clear
color
flexibl
cost
lipophil
absorb
small
organ
chemic
fabric
process
well
hydrophob
drug
compound
introduc
devic
substitut
pdm
still
investig
candid
polystyren
ps
high
modulu
elast
propos
fabric
lungonachip
system
requir
signific
mechan
deform
nonetheless
doubt
polym
accur
mimic
natur
ecm
organ
intend
mimic
even
protein
layer
form
polym
bioactiv
conform
protein
differ
natur
tissu
biolog
standpoint
cultur
cell
organonachip
system
especi
studi
infecti
diseas
remain
challeng
sinc
vitro
cell
cultur
period
current
organonachip
devic
limit
week
suitabl
chronic
longterm
diseas
model
meanwhil
introduct
infecti
bacteria
tissu
cell
cultur
keep
host
tissu
cell
bacteria
distinct
region
microfluid
devic
without
contamin
healthi
cell
reach
confluenc
remain
challeng
secondli
although
incorpor
variou
cell
type
individu
chip
alreadi
accomplish
sever
group
still
benefici
gener
standard
protocol
univers
medium
cultur
differ
cell
type
togeth
addit
due
low
cultur
volum
cell
number
organonachip
microdevic
appropri
organ
scale
also
need
address
accur
replic
physiolog
relev
respons
vivo
ensur
effici
detect
sensit
consequ
compromis
accur
replic
physiolog
complex
control
interact
applic
readout
unavoid
challeng
limit
address
either
valid
comparison
use
model
involv
real
tissu
ensur
appropri
accur
measur
analysi
despit
instrument
role
expand
knowledg
critic
biofilm
biolog
vitro
vitro
model
system
limitationsnot
failur
fulli
recapitul
nativ
host
environ
led
develop
new
wave
sophist
vivo
model
design
better
repres
physiopatholog
condit
human
rang
nonmammalian
model
allow
highthroughput
screen
sophist
mammalian
model
overcom
high
cost
ethic
concern
associ
mammalian
model
system
nonmammalian
model
drosophila
melanogast
fruit
fli
danio
rerio
zebrafish
increasingli
use
studi
bacteri
colon
biofilm
develop
presenc
host
immun
system
model
advantag
compar
mammalian
model
low
cost
easili
maintain
highthroughput
capabl
recognit
import
interspeci
commun
biofilm
develop
nonmammalian
model
even
adapt
studi
polymicrobi
infect
exampl
oropharyng
speci
benefici
fli
singl
speci
infect
identifi
enhanc
p
aeruginosa
virul
coinfect
model
underscor
import
microbemicrob
interact
addit
genom
system
alreadi
fulli
sequenc
genet
manipul
knockin
knockout
model
readili
creat
studi
genet
basi
biofilm
develop
virul
despit
advantag
nonmammalian
host
limit
similar
human
limit
lifespan
therefor
experi
durat
neg
impact
clinic
translat
context
mammal
superior
offer
closest
environ
human
host
tremend
effort
made
develop
mammalian
model
truli
reflect
biofilm
infect
anim
rang
rodent
larger
speci
sheep
pig
consequ
larg
number
vivo
infect
model
avail
target
wide
rang
tissuespecif
infect
deviceassoci
infect
evid
show
vivo
anim
model
produc
similar
biofilm
found
human
infect
bacteria
aggreg
segreg
host
materi
comprehens
list
avail
vivo
model
bacteri
infect
refer
reader
recent
review
histor
procedur
use
inspect
biofilm
develop
vivo
model
system
requir
retriev
infect
tissu
devic
downstream
analysi
make
extrem
difficult
studi
earli
stage
biofilm
format
kinet
develop
recent
advanc
highli
sensit
imag
techniqu
combin
abil
engin
bioluminesc
bacteria
strain
begun
afford
continu
monitor
biofilm
infect
vivo
gener
vivo
model
advantag
provid
opportun
investig
import
question
regard
biofilm
pathogenesi
take
account
import
hostmicrob
interact
difficult
model
vitro
model
therefor
allow
best
transfer
compar
simpl
vitro
model
organsonchip
nonetheless
use
mammalian
vivo
model
restrict
case
due
ethic
consider
project
involv
use
mammalian
model
first
evalu
base
three
r
rule
mammalian
anim
model
use
vitro
model
nonmammalian
model
capabl
address
specif
scientif
question
design
experi
minim
number
anim
requir
obtain
necessari
inform
allevi
potenti
pain
suffer
anim
whenev
involv
partli
explain
vitro
model
vivo
nonmammalian
model
still
heavili
use
scientif
commun
answer
import
question
biofilm
biolog
identifi
potenti
therapeut
strategi
addit
speci
differ
particular
immun
respons
still
exist
vivo
mammalian
model
human
especi
murin
model
fortun
porcin
model
provid
better
translat
potenti
murin
model
due
anatom
physiolog
immunolog
similar
human
exampl
similar
dermal
properti
wound
heal
process
reepitheli
scar
tissu
granul
make
porcin
model
prefer
studi
chronic
wound
infect
delay
wound
heal
success
link
increas
biofilm
characterist
wound
infect
porcin
model
howev
porcin
model
expens
less
access
murin
model
compar
vitro
system
vivo
model
may
also
suffer
larg
variabl
experi
anim
experiment
paramet
often
less
control
final
mammalian
model
often
limit
acut
subchron
experiment
durat
model
biofilm
infect
due
host
respons
ethic
concern
exampl
algin
bead
rat
model
mimic
chronic
lung
infect
limit
lifetim
week
although
issu
could
partli
mitig
repeat
bacteria
exposur
host
resist
reinfect
prevent
option
anim
model
integr
import
interplay
host
immun
system
pathogen
bacteria
lack
chronic
addit
speci
differ
may
explain
high
failur
rate
translat
anim
model
clinic
clearli
applic
vitro
vivo
model
system
caveat
vitro
model
system
often
fail
consid
extrem
complex
microenviron
larg
part
remain
unexplor
experienc
bacteria
human
host
vivo
model
system
invalu
tool
valid
complement
vitro
find
yet
expens
lowthroughput
translat
still
debat
due
speci
differ
limit
prompt
us
develop
ex
vivo
system
sought
decreas
knowledg
gap
vitro
vivo
model
ex
vivo
model
tissu
organ
extract
anim
human
cultur
artifici
environ
use
vitro
method
experiment
one
import
advantag
ex
vivo
system
tradit
vitro
system
even
organonachip
system
preserv
surfac
topographi
architectur
nativ
tissu
grow
bodi
evid
clearli
support
nanoand
microscal
surfac
topographi
huge
influenc
bacteri
attach
bacteri
signal
biofilm
format
instanc
use
microfluid
devic
control
spatial
structur
chemic
commun
found
stabl
coexist
interact
bacteria
requir
defin
microscal
structur
recent
advanc
materi
scienc
also
reveal
reduct
bacteri
adhes
achiev
via
control
surfac
topographi
confirm
role
physiochem
regul
biofilm
format
grow
ex
vivo
sampl
vitro
also
allow
control
reproduc
experiment
condit
permit
realtim
monitor
biofilm
progress
use
techniqu
like
optic
coher
tomographi
particular
use
studi
biofilm
kinet
time
point
earli
bacteri
invas
assess
effect
antimicrobi
biofilm
differ
stage
lastli
use
ex
vivo
tissu
allow
experi
perform
physiolog
relev
environ
would
otherwis
restrict
use
vivo
model
due
ethic
issu
reason
mani
ex
vivo
biofilm
model
system
develop
use
tissu
anim
human
donor
includ
ex
vivo
lung
skin
intestin
segment
dental
mucos
model
disadvantag
maintain
ex
vivo
model
prolong
period
still
challeng
depend
size
geometri
ex
vivo
tissu
adequ
suppli
nutrient
oxygen
throughout
tissu
may
also
issu
follow
discuss
focu
two
commonli
investig
model
ex
vivo
lung
model
ex
vivo
skin
model
highlight
advantag
limit
ex
vivo
model
chronic
lung
infect
associ
cf
tuberculosi
tb
highli
antibiot
resist
often
lethal
develop
effect
prevent
cur
strategi
danger
diseas
reli
deep
understand
diseas
pathogenesi
progress
mani
research
effort
often
focu
key
pathogen
exampl
p
aeruginosa
cf
lung
infect
mycobacterium
tuberculosi
tb
use
vitro
vivo
model
model
system
merit
expand
understand
bacteria
growth
virul
persist
model
certain
limit
discuss
overcom
challeng
cheap
highthroughput
model
chronic
lung
infect
recapitul
nativ
physicochem
environ
critic
need
bridg
gap
vitro
vivo
model
system
toward
end
ex
vivo
lung
model
develop
use
tissu
deriv
rodent
pig
human
donor
sourc
pig
arguabl
best
choic
even
though
tissu
human
donor
clinic
relev
first
porcin
lung
anatom
similar
human
spatial
structur
retain
ex
vivo
porcin
model
recent
evid
suggest
spatial
environ
could
signific
impact
bacteri
interact
growth
virul
second
pig
lung
cheap
readili
avail
butcher
therefor
use
pig
lung
pose
much
less
ethic
concern
compar
use
mice
human
lung
final
singl
porcin
lung
produc
dozen
lung
sampl
kept
cultur
sever
week
combin
inexpens
readili
avail
ex
vivo
model
potenti
use
highthroughput
fashion
two
common
prepar
protocol
wide
use
prepar
ex
vivo
lung
slice
first
method
fig
begin
surfac
decontamin
follow
dissect
tissu
cube
approxim
equal
size
pig
surfac
decontamin
could
carri
briefli
sear
ventral
surfac
pleura
hot
pallet
knife
lung
tissu
prepar
use
method
infect
p
aeruginosa
cultur
artifici
sputum
medium
mimic
chemic
environ
cf
lung
use
ex
vivo
pig
lung
model
p
aeruginosa
growth
quorum
sens
qs
virul
factor
product
tissu
damag
success
quantifi
spatial
structur
environ
close
mimick
chronic
infect
cf
lung
addit
abil
conveni
assess
biofilm
evolut
variou
time
postinocul
use
clsm
open
door
evalu
timedepend
therapeut
window
otherwis
difficult
treat
diseas
similar
techniqu
also
applic
lung
tissu
human
donor
recent
studi
human
ex
vivo
lung
tissu
cultur
model
use
character
initi
phase
mycobacteri
infect
discov
infect
differ
cell
type
earli
mycobacteri
infect
bacteria
speci
depend
unfortun
ex
vivo
lung
model
prepar
follow
procedur
also
limit
import
high
varianc
data
obtain
like
result
tissu
heterogen
inconsist
cut
develop
second
prepar
protocol
precis
cut
lung
slice
pcl
fig
method
improv
consist
cut
offer
possibl
studi
thin
tissu
cultur
pcl
success
appli
tissu
variou
sourc
mice
pig
human
donor
success
use
model
diseas
like
cf
lung
infect
tb
setup
lung
first
subject
infus
low
percentag
lowmelt
point
agaros
solut
airway
pulmonari
arteri
harden
cool
facilit
cut
slice
depend
experi
need
lung
cut
cube
slice
predetermin
thick
use
vibratom
one
advantag
pcl
slice
prepar
one
mous
lung
mani
obtain
lung
larger
speci
rat
pig
human
result
signific
reduct
number
anim
need
similar
ex
vivo
model
plc
retain
much
cellular
divers
spatial
structur
found
nativ
lung
particular
ciliari
function
preserv
plc
confirm
microscop
via
ciliari
motil
provid
opportun
investig
interact
cilia
infecti
agent
allow
us
begin
understand
import
role
diseas
develop
progress
pcl
particularli
use
model
tb
due
signific
differ
mycobacteriainduc
patholog
rel
resist
observ
murin
model
high
cost
associ
nonhuman
primat
model
vitro
model
tb
also
limit
hard
compar
due
use
differ
cell
type
bacteria
strain
infect
dose
cultur
media
diseas
model
plc
hand
preserv
origin
cell
popul
structur
integr
metabol
transport
function
nativ
lung
invalu
gain
new
insight
diseas
mechan
mycobacteri
infect
plc
induc
product
consist
previou
vitro
vivo
studi
demonstr
potenti
bridg
gap
vitro
vivo
model
skin
wound
compromis
wound
heal
major
concern
public
health
affect
million
patient
unit
state
alon
treatment
repres
signific
socioeconom
burden
nation
cost
excess
billion
number
rapidli
grow
due
increas
health
care
cost
age
popul
preval
obes
diabet
high
bacteri
burden
especi
form
biofilm
thought
one
underli
factor
result
nonheal
chronic
wound
studi
investig
wound
heal
human
limit
due
ethic
consider
lead
depend
vitro
vivo
model
system
especi
diseas
pathogenesi
investig
context
robust
easytous
experiment
model
paramount
gain
deeper
understand
infect
pathophysiolog
develop
effect
therapeut
strategi
wound
heal
often
mimick
vitro
creat
defect
cell
monolay
model
howev
recapitul
complex
multicellular
process
wound
infect
wound
heal
system
develop
cultur
cell
matric
hydrogel
improv
model
complex
howev
phenotyp
chang
contractil
fibroblast
observ
matric
due
alter
mechan
tension
presenc
nonphysiolog
level
protein
similar
vitro
model
host
immun
respons
system
interact
also
miss
import
note
consid
chronic
wound
heal
longterm
coher
process
among
cell
growth
factor
cytokin
ecm
protein
altern
anim
model
chronic
skin
wound
heal
develop
gener
import
inform
hostbacteria
interact
evalu
treatment
strategi
clinic
relev
environ
howev
anim
model
expens
compat
highthroughput
screen
larg
number
therapeut
strategi
addit
anatom
physiolog
differ
anim
except
pig
human
skin
combin
artificiallyinduc
nonhuman
patholog
invari
c
schemat
diagram
assembl
model
studi
anaerob
bacteria
bodrum
skin
cultur
model
result
differ
heal
kinet
uniqu
complic
pig
skin
anatom
similar
human
skin
wound
heal
pig
found
similar
human
unfortun
use
pig
associ
higher
cost
requir
special
facil
anim
keep
applic
treatment
also
potenti
challeng
anim
model
prevent
measur
taken
prevent
anim
lick
infect
site
light
limit
ex
vivo
model
use
pig
skin
skin
human
donor
substrat
bacteri
attach
primari
sourc
nutrit
emerg
cheap
highthroughput
altern
close
mimic
vivo
physiochem
environ
exampl
pig
skin
obtain
directli
slaughterhous
steril
chlorin
ga
without
affect
histolog
properti
epidermi
dermi
steril
skin
explant
inocul
clinic
isol
p
aeruginosa
wild
type
strain
aureu
atcc
produc
clinic
relev
biofilm
matur
biofilm
form
explant
increas
toler
antibiot
skin
penetr
dermal
matrix
similar
observ
human
wound
bed
suggest
potenti
model
chronic
wound
infect
human
serv
screen
tool
discov
new
antimicrobi
exampl
porcin
skin
explant
model
use
evalu
abil
surfactantbas
wound
dress
reduc
biofilm
provid
first
evid
poloxam
gel
play
signific
role
sensit
viabl
bacteri
biofilm
similarli
antimicrobi
efficaci
antimicrobi
dress
assess
biofilm
differ
level
matur
use
ex
vivo
model
result
obtain
model
similar
observ
vivo
pig
burn
wound
model
confirm
good
correl
ex
vivo
vivo
model
advantag
use
pig
skin
model
chronic
wound
cheap
readili
avail
use
fresh
frozen
similar
human
skin
anatomi
physiolog
howev
model
involv
biofilm
form
p
aeruginosa
applic
model
clinic
isol
establish
matur
biofilm
remain
seen
ex
vivo
skin
model
also
develop
studi
anaerob
bacteri
infect
anaerob
bacteria
form
signific
proport
microbi
popul
chronic
wound
infect
instanc
skin
explant
surgic
gauz
place
steril
agaros
plug
agaros
pedest
fig
allow
equilibr
co
h
creat
microenviron
restrict
oxygen
suppli
inocul
fastidi
anaerob
agar
plug
confluent
dichelobact
nodosu
nodosu
plate
incub
anaerob
use
model
anaerob
bacteria
nodosu
could
cultur
subsequ
found
alter
express
key
inflammatori
marker
within
skin
standard
ex
vivo
skin
model
allow
skin
explant
cultur
airliquid
interfac
bodrum
system
fig
develop
robust
easi
use
reusabl
ex
vivo
fullskin
cultur
system
cultur
skin
explant
airliquid
interfac
allow
natur
matur
keratinocyt
help
preserv
skin
barrier
function
addit
separ
dermal
epiderm
layer
restrict
bacteria
andor
treatment
specifi
area
without
worri
cross
contamin
advantag
system
includ
defin
tissu
tension
viabil
tissu
week
although
ex
vivo
model
provid
cheap
highthroughput
altern
vivo
model
share
common
limit
similar
vitro
model
one
major
disadvantag
ex
vivo
model
lack
natur
immun
system
migrat
cell
blood
lung
skin
immun
respons
assess
cultur
condit
ex
vivo
model
also
deviat
natur
environ
found
anim
model
although
synthet
media
develop
mimic
nativ
environ
final
lifespan
ex
vivo
model
often
limit
compar
timespan
chronic
infect
emerg
antibiot
resist
bacteria
need
new
antimicrobi
critic
ever
consequ
model
system
repres
nativ
diseas
condit
requir
elucid
mechan
diseas
pathogenesi
also
determin
safeti
efficaci
new
antimicrobi
although
anim
model
still
consid
gold
standard
reflect
predict
human
respons
emerg
evid
point
signific
anatom
physiolog
patholog
differ
among
differ
speci
lead
poor
clinic
translat
addit
vivo
model
often
lack
abil
provid
control
experiment
condit
mechanist
understand
diseas
etiolog
highthroughput
manner
recent
use
anim
biomed
research
also
seriou
scrutini
due
ethic
concern
consequ
simpl
vitro
model
mtpbase
flowbas
system
still
heavili
reli
upon
due
lowcost
easi
setup
amen
high
throughput
design
contribut
mechanist
understand
bacteri
infect
etiolog
virul
howev
mani
vitro
method
contain
nutrient
fluid
flow
surfac
microorgan
repres
vivo
environ
put
question
clinic
relev
effort
negat
differ
includ
use
synthet
media
mimic
nutrient
environ
vivo
wherea
employ
surfaceindepend
method
produc
biofilm
similar
size
shape
antibiot
toler
observ
vitro
nonetheless
simpl
vitro
model
contain
one
bacteria
speci
therefor
lack
microbemicrob
hostmicrob
interact
import
diseas
pathogenesi
progress
virul
convers
although
convent
model
cell
cultur
transwel
plate
provid
opportun
incorpor
host
compon
easi
access
manipul
cultur
paramet
unabl
replic
organ
structur
integr
physiolog
function
present
vivo
environment
condit
blood
vessel
fluid
flow
shear
stress
cyclic
stressstretch
result
improv
made
effort
provid
simplifi
platform
cultur
tissuelik
even
organlik
structur
also
success
replic
function
human
organ
system
microenviron
mani
group
confirm
bioengin
system
vitro
organoid
organonachip
system
ex
vivo
tissu
model
enabl
mimicri
complex
organ
pathophysiolog
allow
indepth
understand
mechan
action
see
tabl
system
therefor
suitabl
develop
humanrelev
diseas
model
predict
drug
efficaci
toxic
patient
particular
ex
vivo
model
infect
attempt
combin
best
vitro
vivo
system
addit
retain
structur
nativ
substrat
origin
cell
type
ex
vivo
studi
carri
greater
control
experiment
condit
allow
mechanist
investig
studi
clariti
worth
note
lifespan
ex
vivo
model
still
limit
may
restrict
applic
studi
chronic
infect
rapid
advanc
sophist
microfluid
system
better
mimic
nutrient
oxygen
suppli
even
physic
forc
may
remedi
prolong
tissu
cultiv
period
futur
perspect
import
keep
mind
major
chronic
infect
harbor
polymicrobi
commun
thu
incorpor
multipl
bacteri
speci
infect
model
like
produc
data
clinic
relev
one
scarciti
current
model
involv
polymicrobi
infect
like
due
difficulti
interpret
data
result
complex
host
tabl
exampl
establish
organ
infect
inflamm
model
group
b
streptococcu
gb
organoid
employ
forbrain
organoid
model
zikv
exposur
humaninduc
pluripot
stem
cell
ipsc
zikv
ex
vivo
model
use
organotyp
brain
slice
cultur
model
viral
enceph
mice
organotyp
brain
slice
cultur
reoviru
serotyp
strain
abney
shi
et
al
biomateri
microb
microbemicrob
interact
improv
understand
specif
interact
cellcel
cellbacteria
effect
pharmaceut
agent
ex
vivo
vitro
model
sophist
welldevelop
simulationanalyz
method
requir
signific
progress
potenti
made
integr
comput
model
tool
metabol
multicel
model
allow
predict
bacteri
behavior
context
complex
host
dynam
specif
vitro
system
organonachip
develop
comput
program
continu
monitor
cell
bacteria
behavior
give
us
opportun
studi
mechan
behind
natur
reaction
drug
treatment
patholog
respons
comprehens
addit
develop
nanotechnolog
nanofabr
also
tremend
help
advanc
understand
multispeci
interact
allow
unpreced
control
bacteri
microenviron
nanoscal
permit
examin
cellular
interact
singl
cell
level
better
understand
spatial
tempor
interact
microb
host
environ
help
advanc
diseas
model
vitro
ex
vivo
vivo
may
also
open
new
way
therapeut
intervent
era
person
medicin
establish
patientspecif
diseas
model
mimic
multisit
wholebodi
patholog
physiolog
faith
recapitul
complex
organlevel
interact
rapidli
evalu
system
respons
drug
candid
provid
highthroughput
analysi
safeti
efficaci
may
interest
clinic
pharmaceut
biotech
industri
instanc
recent
biotechnolog
breakthrough
ipsc
technolog
includ
develop
patientspecif
neural
liver
cardiac
brain
tissu
model
viral
bacteri
infect
patientspecif
ipscderiv
vitro
diseas
model
provid
versatil
noninvas
platform
allow
investig
patientpathogen
interact
discoveri
person
medicin
convers
expos
patientderiv
virus
hbv
bacteria
establish
vitro
model
provid
us
opportun
analyz
patientspecif
immun
respons
toward
infect
thu
enabl
understand
discov
immun
evas
pathway
biomark
addit
current
model
repres
chronic
diseas
maintain
structur
integr
biolog
viabil
longterm
cultur
exposur
pharmaceut
remain
unsolv
therapeut
develop
point
view
exist
vitro
ex
vivo
model
still
prototyp
still
need
substanti
valid
standard
intern
regulatori
bodi
defin
result
obtain
assay
supplementari
data
relat
articl
found
http
